Page last updated: 2024-08-21

hydrazine and Anemia, Aplastic

hydrazine has been researched along with Anemia, Aplastic in 98 studies

Research

Studies (98)

TimeframeStudies, this research(%)All Research%
pre-19901 (1.02)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's53 (54.08)24.3611
2020's44 (44.90)2.80

Authors

AuthorsStudies
Groarke, EM; Gutierrez-Rodrigues, F; Lotter, J; Patel, BA; Quinones Raffo, D; Rios, O; Shalhoub, R; Wu, CO; Young, NS1
Angelucci, E; Barcellini, W; Barraco, F; Cacace, F; Cavenagh, J; Clement, L; Cook, R; Daguindau, E; de Groot, MR; Drexler, B; Dufour, C; Forcade, E; Frieri, C; Griffin, M; Halkes, CJM; Hill, A; Iacobelli, S; Iori, AP; Jarque, I; Kulasekararaj, A; La Rocca, U; Marano, L; Marotta, S; Marsh, JCW; Mear, JB; Mufti, GJ; Munir, T; Muus, P; Nur, E; Palmisani, E; Passweg, JR; Peffault de Latour, R; Praire, A; Rabian, F; Raymakers, RAP; Recher, C; Risitano, AM; Russell, NH; Sánchez-Ortega, I; Sicre de Fontbrune, F; Smith, AE; Socié, G; Sureda, A; Tavitian, S; Terriou, L; Terwel, SR; Tjon, JML; Vallejo, JC; van Lint, MT; Xicoy, B1
Li, MJ; Liu, XJ; Song, YP; Wei, XD; Xiong, YY; Yuan, FF; Zhang, LN; Zhang, QL; Zhou, H1
Grabowski, DR; Guan, Y; Hasipek, M; Jha, BK; Jiang, D; Kongkiatkamon, S; LaFramboise, T; Lindner, D; Maciejewski, JP; Mian, OY; Pagliuca, S; Parker, Y; Patel, B; Saunthararajah, Y; Sekeres, MA; Singh, S; Tiwari, AD1
Eguchi, H; Eguchi, K; Ishimura, M; Kakiuchi, T; Koga, D; Matsuo, M; Nishi, M; Sonoda, M1
Calvo, KR; Desmond, R; Dunbar, CE; Fan, X; Groarke, EM; Larochelle, A; Patel, B; Winkler, T; Young, DJ; Young, NS1
Chen, Y; Huang, F; Li, JY; Qiao, C; Shen, WY; Wang, R; Wang, Y; Zha, Q1
Horiuchi, T; Izumi, T; Kawamura, T; Kimura, F; Kobayashi, S; Sato, K; Takano, K1
Chan, FHY; Chan, KP; Chan, TSY; Hwang, YY; Kho, B; Kwong, YL; Lau, CK; Lau, CWP; Lau, GWN; Lau, JSM; Leung, KH; Lin, SY; Luk, YY; Mak, V; Sim, JPY; Yip, SF1
He, GS; Huang, LF; Jia, JS; Li, L; Lin, SY; Meng, FK; Yang, Y; Zhang, DH1
Arita, K; Hosono, N; Imi, T; Iwaki, N; Murakami, J; Nakao, S; Nannya, Y; Ogawa, S; Okazawa, H; Tasaki, T; Tsujikawa, T1
Chen, M; Han, B; Liu, B; Zhang, B; Zuo, W1
Fu, R; Han, B; Jiao, W; Lei, M; Liu, L; Liu, R; Miao, M; Wu, D; Zhang, F; Zhang, L; Zhang, Y; Zhao, X1
He, G; Jia, J; Jin, Y; Li, J; Li, R; Lin, S; Yang, Y; Zhang, D1
Barth, D; Benitez, LL; Bixby, D; Buhlinger, KM; Burke, P; Desai, R; Marini, BL; Perissinotti, AJ; Pettit, K; Reid, JH; Shinn, LT; Soule, A; Stump, SE; van Deventer, H; Wagner, CB; Weis, TM; Zacholski, K1
Chang, H; Fu, R; Han, B; He, G; Jin, H; Li, F; Li, T; Liu, L; Mittal, H; Zhang, F1
Andreani, G; Cilloni, D; De Gobbi, M; Dragani, M; Saglio, G1
Arcona, S; Cai, B; Li, FY; Li, X; Said, Q1
Advani, A; Barot, SV; Carraway, HE; Kalaycio, M; Kerr, C; Kuzmanovic, T; Lee, S; Lichtin, A; Maciejewski, JP; Patel, BJ; Patel, S; Przychodzen, BP; Radivoyevitch, T; Sekeres, MA; Thota, S1
Antin, J; Bilginsoy, M; Duh, MS; Huynh, L; Ivanova, JI; Peffault de Latour, R; Roy, A; Totev, T1
Gao, Q; Guan, D; Hu, J; Liu, X; Zhang, F; Zhu, Y1
Alemu, L; Feng, X; Groarke, EM; Kajigaya, S; Patel, BA; Quinones Raffo, D; Young, NS; Zaimoku, Y1
Albitar, M; Barranta, ME; Calvo, KR; Desmond, R; Dumitriu, B; Dunbar, CE; Fan, X; Gutierrez-Rodrigues, F; Lotter, J; Sellers, SE; Shalhoub, RN; Townsley, DM; Valdez, J; Winkler, T; Wu, CO; Young, DJ; Young, NS1
Hangaishi, A; Hirao, M; Iizuka, H; Kamoda, Y; Kida, M; Uchibori, Y; Usuki, K1
Cheng, H; Wang, X; Xu, KL1
Babushok, DV; Sun, L1
Avgerinou, G; Filippidou, M; Katsibardi, K; Kattamis, A; Roka, K; Solomou, E; Tourkantoni, N; Tsipou, H; Vlachou, A1
Hosokawa, K; Imi, T; Nakao, S; Sugimori, N; Tanabe, M; Yamazaki, H1
Al-Samkari, H; Goodarzi, K1
Hirao, M; Iizuka, H; Ise, M; Kamoda, Y; Kida, M; Usuki, K1
Chen, M; Han, B; Ruan, J; Yang, C; Zuo, W1
Babushok, D; Bagg, A; Hurwitz, SN; Juusola, J; Sklarz, T; Stanley, NL1
Calado, RT; Catto, LFB; Quintino de Oliveira, B; Santana, BAA; Scheinberg, P; Scheucher, PS; Tellechea, MF1
Fanghong, Z; Hombo, Y; Iida, H; Imada, K; Imajo, K; Kumagai, A; Maeda, T; Matsuda, A; Nakao, S; Obara, N; Tajima, T; Usuki, K1
Olson, TS1
Baldoni, D; Groarke, EM; Gutierrez-Rodrigues, F; Lotter, J; Patel, BA; Rios, O; Shalhoub, R; St Pierre, A; Townsley, DM; Wu, CO; Young, NS1
Chiu, V; Hermel, D; Martynova, A; Mert, M; Weitz, IC1
Cheng, X; Fu, L; He, Y; Jie, M; Li, S; Wu, R; Yao, J; Zhang, L; Zhang, R; Zheng, J1
Scheinberg, P4
Boals, M; Ding, J; Gray, N; Hale, M; Jacobs, T; Kang, G; Lesmana, H; Lewis, S; Reiss, U; Wang, W; Weiss, M; Wlodarski, M1
Feng, X; Groarke, EM; Patel, BA; Shalhoub, R; Wu, CO; Young, NS; Zaimoku, Y1
Chen, L; Han, S; Liu, J; Peng, Y; Wang, H; Wu, Y; Zhang, J1
Huan Ng, C; Jang-Milligan, F; Schultz, KR1
Chang, HH; Chou, SW; Jou, ST; Lin, DT; Lin, KH; Lu, MY; Su, MY; Yang, YL1
Bevans, M; Calvo, KR; Desierto, M; Desmond, R; Dumitriu, B; Dunbar, CE; Feng, X; Larochelle, A; Leuva, H; Lotter, J; Rios, O; Scheinberg, P; Townsley, DM; Valdez, J; Weinstein, B; Winkler, T; Wu, C; Young, NS1
Bonfim, C; George, B; Kumar, R1
Desmond, R; Dumitriu, B; Dunbar, CE; Feng, X; Olnes, M; Townsley, DM; Winkler, T; Wu, Z; Young, NS; Zhao, X1
Abraham, J; Ades, L; Balsat, M; Berceanu, A; Chaoui, D; Coppo, P; Corm, S; de Fontbrune, FS; de Latour, RP; Drenou, B; Dupriez, B; Guillerm, G; Leblanc, T; Lengline, E; Maillard, N; Peterlin, P; Raffoux, E; Socié, G; Terriou, L; Tournilhac, O1
Chan, TSY; Cheung, CYM; Gill, H; Hwang, YY; Kwong, YL; Leung, GMK1
Adam, S; Alharthi, S; Anyfantis, G; Armstrong, L; Barta, T; El-Harouni, AA; Elango, R; Gassner, K; Lako, M; Melguizo-Sanchis, D; Przyborski, S; Samarasinghe, S; Saretzki, G; Taheem, D; Tilgner, K; Wan, T; Xu, Y; Yu, M1
Gilreath, JA; Rodgers, GM1
Cheng, Z; Dunbar, CE; Grasmeder, S; Sokoll, LJ; Streiff, M; Sun, Q; Townsley, DM; Winkler, T; Young, NS; Zhao, Z1
Lázaro Rodríguez, I; Pérez Alonso, V; Rubio-San-Simón, A; Vázquez Gómez, F; Vivanco Martínez, JL1
Geng, W; Kearney, S; Nelson, S1
Gilreath, JA; Kurtti, AL; Rodgers, GM1
Fu, L; Li, S; Ma, J; Qin, M; Wang, B; Wu, R; Zhang, L; Zhou, X; Zhu, G1
Alvarado, Y; Assi, R; Borthakur, G; Burger, J; Cortes, J; Daver, NG; Dinardo, CD; Estrov, Z; Ferrajoli, A; Garcia-Manero, G; Hendrickson, S; Jabbour, E; Kadia, TM; Kantarjian, H; Ravandi, F; Wierda, W1
Biancotto, A; Candia, J; Cheung, F; Fantoni, G; Feng, X; Giudice, V; Kajigaya, S; Rios, O; Townsley, D; Wu, Z; Young, NS1
Young, NS1
Chen, Y; Hong, Y; Li, N; Li, X; Wan, B1
Arnold, L; Barcellini, W; Benson-Quarm, N; Consonni, D; De Lavallade, H; Fattizzo, B; Griffin, M; Hill, A; Hillmen, P; Ireland, R; Kulasekararaj, AG; Marsh, JCW; Mufti, GJ; Munir, T; Potter, V; Riley, K1
Cao, J; Cheng, H; Larochelle, A; Wang, X; Xu, KL; Zhou, D1
Afanasyev, B; Bonifazi, F; Bosman, P; Bruno, B; Cortelezzi, A; de Latour, RP; Dreger, P; Drénou, B; Drexler, B; Dufour, C; Ecsedi, M; Eikema, DJ; Garnier, A; Giammarco, S; Halkes, CJM; Knol-Bout, C; Lanino, E; Lengline, É; Ljungman, P; Maschan, A; Onofrillo, D; Passweg, J; Patriarca, A; Pioltelli, P; Pulanic, D; Risitano, AM; Rovó, A; Serventi-Seiwerth, R; Tournilhac, O1
Ames, NJ; Barb, JJ; Cashion, AK; Childs, R; Faller, LL; Kim, H; Mudra, SE; Paster, BJ; Ranucci, A; Townsley, DM; Wallen, GR1
Calvo, KR; Cooper, J; Desierto, M; Desmond, R; Dunbar, CE; Fan, X; Grasmeder, S; Larochelle, A; Lotter, J; Scheinberg, P; Shalhoub, RN; Townsley, DM; Valdez, J; Winkler, T; Wu, C; Young, DJ; Young, NS1
Atay, H; Kelkitli, E; Turgut, M1
Arman Bilir, Ö; Işık, M; Kaçar, D; Özbek, NY; Yaralı, HN; Yazal Erdem, A1
Barcellini, W; Cavallaro, F; Fattizzo, B; Milesi, G1
Fanghong, Z; Hattori, T; Iida, H; Imada, K; Imajo, K; Matsuda, A; Miyamura, K; Nakao, S; Obara, N; Ohta, K; Sasaki, O; Tajima, T; Tokumine, Y; Tomiyama, Y; Usuki, K; Yamazaki, H1
Babushok, DV1
Barcellini, W; Cassin, R; Fattizzo, B; Levati, G1
Kulasekararaj, AG; Marsh, JC1
Bevans, M; Broder, K; Calvo, KR; Desmond, R; Dumitriu, B; Dunbar, CE; Olnes, MJ; Parikh, AR; Scheinberg, P; Townsley, DM; Wu, CO; Young, NS1
Nakao, S2
Marsh, JC; Mufti, GJ1
Bryan, J; Kadia, TM; Rexwinkle, A; Willis, L1
Bart-Smith, EE; Kordasti, S; Kulasekararaj, AG; Marsh, JC; Mufti, GJ; Richardson, D1
Höchsmann, B; Körper, S; Schrezenmeier, H1
Desmond, R; Dunbar, C; Townsley, DM; Young, NS1
McCormack, PL1
Locatelli, F; Merli, P; Palumbo, G; Strocchio, L; Vinti, L1
Gounden, V; Zhao, Z1
John, JM; Malhotra, P1
Bown, N; Cavenagh, J; Dokal, I; Foukaneli, T; Hill, A; Hillmen, P; Ireland, R; Killick, SB; Kulasekararaj, A; Marsh, JC; Mufti, G; Samarasinghe, S; Snowden, JA; Wood, A1
Häckel, A1
Gill, H; Kwong, YL; Leung, GM; Lopes, D1
Kazemi, T; Martin, S; Worswick, S1
Grainger, JD; Lum, SH1
Townsley, DM; Winkler, T1
Biancotto, A; Calvo, KR; Desmond, R; Dumitriu, B; Dunbar, CE; Feng, X; Lozier, J; Olnes, MJ; Parikh, AR; Scheinberg, P; Soto, S; Tang, Y; Wu, CO; Young, NS1
Metcalf, D1
Oshima, Y; Tojo, A; Yuji, K1
Akard, L1
Akoun, G; Brocard, H1

Reviews

22 review(s) available for hydrazine and Anemia, Aplastic

ArticleYear
Synergistic effect of eltrombopag and deferasirox in aplastic anemia: a clinical case and review of the literature.
    Leukemia & lymphoma, 2020, Volume: 61, Issue:1

    Topics: Anemia, Aplastic; Benzoates; Deferasirox; Humans; Hydrazines; Pyrazoles

2020
Allo-HSCT compared with immunosuppressive therapy for acquired aplastic anemia: a system review and meta-analysis.
    BMC immunology, 2020, 03-06, Volume: 21, Issue:1

    Topics: Anemia, Aplastic; Animals; Benzoates; Combined Modality Therapy; Hematopoietic Stem Cell Transplantation; Humans; Hydrazines; Immunosuppression Therapy; Pyrazoles; Transplantation, Homologous

2020
Acquired severe aplastic anaemia: how medical therapy evolved in the 20th and 21st centuries.
    British journal of haematology, 2021, Volume: 194, Issue:6

    Topics: Anemia, Aplastic; Animals; Benzoates; Disease Management; Hematopoietic Stem Cell Transplantation; Humans; Hydrazines; Immunosuppression Therapy; Pyrazoles; Severity of Illness Index

2021
A systematic review and meta-analysis of the safety and efficacy of anti-thymocyte globulin combined with eltrombopag in the treatment of severe aplastic anemia.
    Annals of palliative medicine, 2021, Volume: 10, Issue:5

    Topics: Anemia, Aplastic; Antilymphocyte Serum; Benzoates; Humans; Hydrazines; Prospective Studies; Pyrazoles; Treatment Outcome

2021
Has Eltrombopag eliminated the need to use allogeneic HSCT in first line treatment of pediatric aplastic anemia?
    Pediatric hematology and oncology, 2021, Volume: 38, Issue:5

    Topics: Allografts; Anemia, Aplastic; Benzoates; Child; Female; Hematopoietic Stem Cell Transplantation; Humans; Hydrazines; Male; Pyrazoles

2021
Hematopoietic cell transplantation for aplastic anemia.
    Current opinion in hematology, 2017, Volume: 24, Issue:6

    Topics: Allografts; Anemia, Aplastic; Benzoates; Hematopoietic Stem Cell Transplantation; Humans; Hydrazines; Immunosuppression Therapy; Practice Guidelines as Topic; Pyrazoles

2017
Recent Advances and Long-Term Results of Medical Treatment of Acquired Aplastic Anemia: Are Patients Cured?
    Hematology/oncology clinics of North America, 2018, Volume: 32, Issue:4

    Topics: Alemtuzumab; Anemia, Aplastic; Animals; Antilymphocyte Serum; Benzoates; Cyclosporine; Humans; Hydrazines; Immunosuppression Therapy; Immunosuppressive Agents; Pyrazoles; Recurrence; Treatment Outcome

2018
Aplastic Anemia.
    The New England journal of medicine, 2018, Oct-25, Volume: 379, Issue:17

    Topics: Adult; Algorithms; Anemia, Aplastic; Benzoates; Bone Marrow Transplantation; Child; Hematopoietic Stem Cell Transplantation; Humans; Hydrazines; Immunosuppressive Agents; Pyrazoles; Receptors, Thrombopoietin; Transplantation, Homologous

2018
Efficacy and Safety of Eltrombopag for Aplastic Anemia: A Systematic Review and Meta-analysis.
    Clinical drug investigation, 2019, Volume: 39, Issue:2

    Topics: Anemia, Aplastic; Benzoates; Humans; Hydrazines; Immunosuppressive Agents; Pyrazoles

2019
Activity of eltrombopag in severe aplastic anemia.
    Blood advances, 2018, 11-13, Volume: 2, Issue:21

    Topics: Anemia, Aplastic; Benzoates; Blood Cell Count; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Therapy, Combination; Humans; Hydrazines; Immunosuppressive Agents; Pyrazoles; Receptors, Thrombopoietin

2018
Activity of eltrombopag in severe aplastic anemia.
    Hematology. American Society of Hematology. Education Program, 2018, 11-30, Volume: 2018, Issue:1

    Topics: Anemia, Aplastic; Antilymphocyte Serum; Benzoates; Cyclosporine; Disease-Free Survival; Humans; Hydrazines; Pyrazoles; Severity of Illness Index; Survival Rate

2018
Eltrombopag in Immune Thrombocytopenia, Aplastic Anemia, and Myelodysplastic Syndrome: From Megakaryopoiesis to Immunomodulation.
    Drugs, 2019, Volume: 79, Issue:12

    Topics: Anemia, Aplastic; Benzoates; Humans; Hydrazines; Immunomodulation; Immunosuppression Therapy; Megakaryocytes; Myelodysplastic Syndromes; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Thrombopoietin

2019
Management of the refractory aplastic anemia patient: what are the options?
    Hematology. American Society of Hematology. Education Program, 2013, Volume: 2013

    Topics: Adult; Age Factors; Alemtuzumab; Allografts; Anemia, Aplastic; Antibodies, Monoclonal, Humanized; Antilymphocyte Serum; Antineoplastic Agents; Benzoates; Bone Marrow Diseases; Bone Marrow Failure Disorders; Cyclosporine; Disease-Free Survival; Hematopoietic Stem Cell Transplantation; Hemoglobinuria, Paroxysmal; Humans; Hydrazines; Immunosuppression Therapy; Immunosuppressive Agents; Middle Aged; Pyrazoles; Siblings; Survival Rate; Unrelated Donors

2013
[Recent issues and prospects of the treatment of aplastic anemia].
    [Rinsho ketsueki] The Japanese journal of clinical hematology, 2014, Volume: 55, Issue:1

    Topics: Anemia, Aplastic; Animals; Antilymphocyte Serum; Benzoates; Biomarkers; Cyclosporine; Drug Therapy, Combination; Herpesvirus 4, Human; Humans; Hydrazines; Immunosuppressive Agents; Lymphoproliferative Disorders; Prednisolone; Pyrazoles; Receptors, Thrombopoietin; Risk; Severity of Illness Index; Thrombopoietin

2014
Recent developments in drug therapy for aplastic anemia.
    The Annals of pharmacotherapy, 2014, Volume: 48, Issue:11

    Topics: Alemtuzumab; Anemia, Aplastic; Animals; Antibodies, Monoclonal, Humanized; Antilymphocyte Serum; Benzoates; Clinical Trials as Topic; Cyclosporine; Daclizumab; Humans; Hydrazines; Immunoglobulin G; Immunosuppressive Agents; Pyrazoles; Recurrence; Salvage Therapy; Survival Rate

2014
[Recent progress in the management of aplastic anemia].
    [Rinsho ketsueki] The Japanese journal of clinical hematology, 2014, Volume: 55, Issue:10

    Topics: Acute Disease; Anemia, Aplastic; Antilymphocyte Serum; Benzoates; Chronic Disease; Cyclosporine; Disease Progression; Hematopoiesis; Humans; Hydrazines; Immunosuppressive Agents; Pyrazoles

2014
[Aplastic anemia].
    Deutsche medizinische Wochenschrift (1946), 2014, Volume: 139, Issue:49

    Topics: Anemia, Aplastic; Antilymphocyte Serum; Benzoates; DNA Mutational Analysis; Drug Therapy, Combination; Early Medical Intervention; Hematopoietic Stem Cell Transplantation; Hemoglobinuria, Paroxysmal; Humans; Hydrazines; Immunosuppressive Agents; Myelodysplastic Syndromes; Prognosis; Pyrazoles; Randomized Controlled Trials as Topic; Shelterin Complex; Telomerase; Telomere-Binding Proteins; Transplantation Conditioning

2014
Eltrombopag in aplastic anemia.
    Seminars in hematology, 2015, Volume: 52, Issue:1

    Topics: Anemia, Aplastic; Animals; Benzoates; Hematopoiesis; Humans; Hydrazines; Pyrazoles; Recurrence; Risk Factors; Thrombopoietin

2015
Eltrombopag: a review of its use in patients with severe aplastic anaemia.
    Drugs, 2015, Volume: 75, Issue:5

    Topics: Anemia, Aplastic; Animals; Benzoates; Hematinics; Hematopoiesis; Humans; Hydrazines; Practice Guidelines as Topic; Pyrazoles; Receptors, Thrombopoietin; Severity of Illness Index

2015
Eltrombopag for treatment of thrombocytopenia-associated disorders.
    Expert opinion on pharmacotherapy, 2015, Volume: 16, Issue:14

    Topics: Anemia, Aplastic; Animals; Benzoates; Chronic Disease; Clinical Trials as Topic; Hematopoietic Stem Cell Transplantation; Hepatitis, Chronic; Humans; Hydrazines; Myelodysplastic Syndromes; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Thrombopoietin; Thrombocytopenia; Thrombopoiesis

2015
Eltrombopag for the treatment of aplastic anemia: current perspectives.
    Drug design, development and therapy, 2016, Volume: 10

    Topics: Alemtuzumab; Anemia, Aplastic; Antibodies, Monoclonal, Humanized; Antilymphocyte Serum; Benzoates; Cyclophosphamide; Cyclosporine; Hematopoietic Stem Cells; Humans; Hydrazines; Immunosuppressive Agents; Pyrazoles

2016
Nontransplant therapy for bone marrow failure.
    Hematology. American Society of Hematology. Education Program, 2016, Dec-02, Volume: 2016, Issue:1

    Topics: Anemia, Aplastic; Anemia, Refractory; Benzoates; Danazol; Humans; Hydrazines; Immunosuppression Therapy; Pyrazoles

2016

Trials

15 trial(s) available for hydrazine and Anemia, Aplastic

ArticleYear
Long-term outcomes in patients with severe aplastic anemia treated with immunosuppression and eltrombopag: a phase 2 study.
    Blood, 2022, 01-06, Volume: 139, Issue:1

    Topics: Adult; Anemia, Aplastic; Benzoates; Cyclosporine; Female; Humans; Hydrazines; Immunosuppressive Agents; Male; Middle Aged; Prospective Studies; Pyrazoles; Survival Analysis; Treatment Outcome; Young Adult

2022
Eltrombopag Added to Immunosuppression in Severe Aplastic Anemia.
    The New England journal of medicine, 2022, 01-06, Volume: 386, Issue:1

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anemia, Aplastic; Antilymphocyte Serum; Benzoates; Cyclosporine; Drug Therapy, Combination; Female; Humans; Hydrazines; Immunosuppression Therapy; Immunosuppressive Agents; Male; Middle Aged; Progression-Free Survival; Prospective Studies; Pyrazoles; Receptors, Thrombopoietin; Remission Induction; Young Adult

2022
Efficacy and safety of eltrombopag in Chinese patients with refractory or relapsed severe aplastic anemia.
    Scientific reports, 2023, 11-02, Volume: 13, Issue:1

    Topics: Adult; Anemia, Aplastic; Benzoates; East Asian People; Humans; Hydrazines; Immunosuppressive Agents; Prospective Studies; Treatment Outcome

2023
Eltrombopag for patients with moderate aplastic anemia or uni-lineage cytopenias.
    Blood advances, 2020, 04-28, Volume: 4, Issue:8

    Topics: Anemia, Aplastic; Benzoates; Humans; Hydrazines; Prospective Studies; Pyrazoles

2020
Longitudinal evaluation of eltrombopag in paediatric acquired severe aplastic anaemia.
    British journal of haematology, 2020, Volume: 190, Issue:3

    Topics: Adolescent; Anemia, Aplastic; Antilymphocyte Serum; Benzoates; Child; Child, Preschool; Cyclosporine; Female; Follow-Up Studies; Humans; Hydrazines; Immunosuppressive Agents; Male; Off-Label Use; Pyrazoles; Receptors, Thrombopoietin; Treatment Outcome

2020
Eltrombopag in Combination with Rabbit Anti-thymocyte Globulin/Cyclosporine A in Immunosuppressive Therapy-naïve Patients with Aplastic Anemia in Japan.
    Internal medicine (Tokyo, Japan), 2021, Apr-15, Volume: 60, Issue:8

    Topics: Anemia, Aplastic; Antilymphocyte Serum; Benzoates; Cyclosporine; Humans; Hydrazines; Immunosuppressive Agents; Japan; Neoplasm Recurrence, Local; Pyrazoles; Treatment Outcome

2021
Eltrombopag added to immunosuppression for children with treatment-naïve severe aplastic anaemia.
    British journal of haematology, 2021, Volume: 192, Issue:3

    Topics: Adolescent; Anemia, Aplastic; Antilymphocyte Serum; Benzoates; Child; Cyclosporine; Female; Humans; Hydrazines; Immunosuppressive Agents; Male; Pyrazoles; Treatment Outcome

2021
Eltrombopag Added to Standard Immunosuppression for Aplastic Anemia.
    The New England journal of medicine, 2017, 04-20, Volume: 376, Issue:16

    Topics: Adolescent; Adult; Aged; Anemia, Aplastic; Antigens, CD34; Antilymphocyte Serum; Benzoates; Cell Count; Cyclosporine; Drug Therapy, Combination; Female; Hematologic Agents; Humans; Hydrazines; Immunosuppression Therapy; Immunosuppressive Agents; Male; Middle Aged; Prospective Studies; Pyrazoles; Receptors, Thrombopoietin; Young Adult

2017
Persistent elevation of plasma thrombopoietin levels after treatment in severe aplastic anemia.
    Experimental hematology, 2018, Volume: 58

    Topics: Adolescent; Adult; Aged; Anemia, Aplastic; Benzoates; Child; Female; Humans; Hydrazines; Immunosuppression Therapy; Male; Middle Aged; Platelet Count; Pyrazoles; Severity of Illness Index; Thrombopoietin; Time Factors

2018
Addition of eltrombopag to immunosuppressive therapy in patients with newly diagnosed aplastic anemia.
    Cancer, 2018, 11-01, Volume: 124, Issue:21

    Topics: Adult; Aged; Aged, 80 and over; Anemia, Aplastic; Benzoates; Drug Therapy, Combination; Female; Granulocyte Colony-Stimulating Factor; Humans; Hydrazines; Immunosuppressive Agents; Male; Middle Aged; Pyrazoles; Remission Induction; Survival Analysis; Treatment Outcome; Young Adult

2018
Treatment optimization and genomic outcomes in refractory severe aplastic anemia treated with eltrombopag.
    Blood, 2019, 06-13, Volume: 133, Issue:24

    Topics: Anemia, Aplastic; Benzoates; Clonal Evolution; Female; Humans; Hydrazines; Male; Pyrazoles

2019
Hematologic recovery induced by eltrombopag in Japanese patients with aplastic anemia refractory or intolerant to immunosuppressive therapy.
    International journal of hematology, 2019, Volume: 110, Issue:2

    Topics: Adult; Aged; Anemia, Aplastic; Benzoates; Blood Transfusion; Cell Lineage; Chemical and Drug Induced Liver Injury; Combined Modality Therapy; Drug Resistance; Drug Substitution; Female; Hematopoiesis; Humans; Hydrazines; Immunosuppressive Agents; Japan; Male; Middle Aged; Pharyngitis; Platelet Count; Pyrazoles; Receptors, Thrombopoietin; Treatment Outcome; Young Adult

2019
Eltrombopag restores trilineage hematopoiesis in refractory severe aplastic anemia that can be sustained on discontinuation of drug.
    Blood, 2014, Mar-20, Volume: 123, Issue:12

    Topics: Adolescent; Adult; Aged; Anemia, Aplastic; Benzoates; Bone Marrow; Clonal Evolution; Female; Hematologic Agents; Hematopoiesis; Hematopoietic Stem Cells; Humans; Hydrazines; Immunosuppressive Agents; Male; Middle Aged; Pyrazoles; Receptors, Thrombopoietin; Young Adult

2014
[Thrombopoietin receptor agonist arouses new hope].
    MMW Fortschritte der Medizin, 2016, Apr-14, Volume: 158, Issue:7

    Topics: Anemia, Aplastic; Benzoates; Drug Approval; Hematopoietic Stem Cells; Humans; Hydrazines; Pyrazoles; Receptors, Thrombopoietin

2016
Eltrombopag and improved hematopoiesis in refractory aplastic anemia.
    The New England journal of medicine, 2012, Jul-05, Volume: 367, Issue:1

    Topics: Adolescent; Adult; Aged; Anemia, Aplastic; Benzoates; Bone Marrow Cells; Chronic Disease; Drug Resistance; Female; Humans; Hydrazines; Male; Middle Aged; Pyrazoles; Recurrence; Young Adult

2012

Other Studies

61 other study(ies) available for hydrazine and Anemia, Aplastic

ArticleYear
[Efficacy and safety analysis of eltrombopag and recombinant human thrombopoietin combined with immunosuppressive therapy for severe aplastic anemia].
    Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2021, Dec-14, Volume: 42, Issue:12

    Topics: Anemia, Aplastic; Benzoates; Humans; Hydrazines; Immunosuppression Therapy; Immunosuppressive Agents; Pyrazoles; Retrospective Studies; Thrombopoietin

2021
Eltrombopag inhibits TET dioxygenase to contribute to hematopoietic stem cell expansion in aplastic anemia.
    The Journal of clinical investigation, 2022, 02-15, Volume: 132, Issue:4

    Topics: Anemia, Aplastic; Animals; Benzoates; Cell Proliferation; Dioxygenases; DNA-Binding Proteins; Hematopoietic Stem Cells; Humans; Hydrazines; Mice; Mice, Knockout; Pyrazoles

2022
Changes in bone marrow and peripheral blood lymphocyte subset findings with onset of hepatitis-associated aplastic anemia.
    Medicine, 2022, Feb-25, Volume: 101, Issue:8

    Topics: Anemia, Aplastic; Benzoates; Bone Marrow; Cytomegalovirus Infections; Hepatitis; Humans; Hydrazines; Infant; Killer Cells, Natural; Lymphocyte Subsets; Lymphocytes; Male; Pyrazoles; Receptors, Thrombopoietin

2022
Long-term eltrombopag for bone marrow failure depletes iron.
    American journal of hematology, 2022, 06-01, Volume: 97, Issue:6

    Topics: Anemia, Aplastic; Benzoates; Ferritins; Humans; Hydrazines; Iron; Iron Overload; Pancytopenia; Pyrazoles; Recurrence; Thrombocytopenia

2022
[The efficacy of eltrombopag plus cyclosporine A in patients with transfusion-dependent non-severe aplastic anemia: a retrospective study from single center].
    Zhonghua nei ke za zhi, 2022, Apr-01, Volume: 61, Issue:4

    Topics: Anemia, Aplastic; Antilymphocyte Serum; Benzoates; Cyclosporine; Humans; Hydrazines; Immunosuppressive Agents; Pyrazoles; Retrospective Studies

2022
[Successful treatment of secondary graft failure after allogeneic stem cell transplantation for aplastic anemia with eltrombopag].
    [Rinsho ketsueki] The Japanese journal of clinical hematology, 2022, Volume: 63, Issue:3

    Topics: Adult; Anemia, Aplastic; Benzoates; Female; Hematopoietic Stem Cell Transplantation; Humans; Hydrazines; Male; Pyrazoles

2022
Eltrombopag as frontline treatment of aplastic anaemia in routine practice: implications on cost and efficacy.
    Annals of hematology, 2022, Volume: 101, Issue:6

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anemia, Aplastic; Antilymphocyte Serum; Benzoates; Cyclosporine; Female; Humans; Hydrazines; Immunosuppressive Agents; Male; Middle Aged; Pyrazoles; Treatment Outcome; Young Adult

2022
Frontline Therapy Options for Adults With Newly Diagnosed Severe Aplastic Anemia: Intensive immunosuppressive Therapy Plus Eltrombopag or Matched Sibling Donor Hematopoietic Stem Cell Transplantation?
    Transplantation and cellular therapy, 2022, Volume: 28, Issue:9

    Topics: Anemia, Aplastic; Animals; Benzoates; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Hydrazines; Immunosuppression Therapy; Pyrazoles; Siblings; Swine

2022
An eltrombopag-induced remission of bone-marrow aplasia accompanied by marked leukoerythroblastosis and splenomegaly.
    British journal of haematology, 2022, Volume: 198, Issue:5

    Topics: Anemia, Aplastic; Benzoates; Bone Marrow; Humans; Hydrazines; Pyrazoles; Splenomegaly

2022
Relationship between CYP2C8, UGT1A1, and ABCG2 gene polymorphisms and the exposure, efficacy, and toxicity of eltrombopag in the treatment of refractory aplastic anemia.
    European journal of clinical pharmacology, 2022, Volume: 78, Issue:10

    Topics: Anemia, Aplastic; ATP Binding Cassette Transporter, Subfamily G, Member 2; Benzoates; Camptothecin; Cytochrome P-450 CYP2C8; Genotype; Glucuronosyltransferase; Humans; Hydrazines; Neoplasm Proteins; Polymorphism, Genetic; Pyrazoles

2022
Matched related transplantation versus immunosuppressive therapy plus eltrombopag for first-line treatment of severe aplastic anemia: a multicenter, prospective study.
    Journal of hematology & oncology, 2022, 08-12, Volume: 15, Issue:1

    Topics: Adult; Anemia, Aplastic; Benzoates; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Hydrazines; Immunosuppression Therapy; Immunosuppressive Agents; Prospective Studies; Pyrazoles; Retrospective Studies; Treatment Outcome

2022
A real-word experience of eltrombopag plus rabbit antithymocyte immunoglobulin-based IST in Chinese patients with severe aplastic anemia.
    Annals of hematology, 2022, Volume: 101, Issue:11

    Topics: Anemia, Aplastic; Antilymphocyte Serum; Benzoates; China; Cyclosporine; Humans; Hydrazines; Immunosuppression Therapy; Immunosuppressive Agents; Pyrazoles; Receptors, Thrombopoietin; Treatment Outcome

2022
Multicenter evaluation of the addition of eltrombopag to immunosuppressive therapy for adults with severe aplastic anemia.
    International journal of hematology, 2023, Volume: 118, Issue:6

    Topics: Adult; Anemia, Aplastic; Benzoates; Humans; Hydrazines; Immunosuppression Therapy; Immunosuppressive Agents; Retrospective Studies

2023
Healthcare resource use and direct costs in severe aplastic anemia (SAA) patients before and after treatment with eltrombopag.
    Journal of medical economics, 2020, Volume: 23, Issue:3

    Topics: Adult; Age Factors; Aged; Anemia, Aplastic; Antineoplastic Agents; Benzoates; Comorbidity; Female; Health Expenditures; Health Resources; Hospitalization; Humans; Hydrazines; Insurance Claim Review; Male; Middle Aged; Patient Acceptance of Health Care; Pyrazoles; Residence Characteristics; Retrospective Studies; Sex Factors; Socioeconomic Factors

2020
Distinctive and common features of moderate aplastic anaemia.
    British journal of haematology, 2020, Volume: 189, Issue:5

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Algorithms; Anemia, Aplastic; Autoimmune Diseases; Benzoates; Blood Transfusion; Bone Marrow; Child; Child, Preschool; Clonal Evolution; Combined Modality Therapy; Danazol; Disease Management; Disease Progression; Female; Hematopoiesis; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Hemoglobinuria, Paroxysmal; Humans; Hydrazines; Immunosuppressive Agents; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Pyrazoles; Severity of Illness Index; Young Adult

2020
Burden of illness among patients with severe aplastic anemia who have had insufficient response to immunosuppressive therapy: a multicenter retrospective chart review study.
    Annals of hematology, 2020, Volume: 99, Issue:4

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anemia, Aplastic; Antilymphocyte Serum; Benzoates; Blood Transfusion; Boston; Combined Modality Therapy; Cost of Illness; Drug Resistance; Female; Follow-Up Studies; Health Resources; Hematopoietic Stem Cell Transplantation; Humans; Hydrazines; Immunosuppressive Agents; Infections; Kaplan-Meier Estimate; Male; Middle Aged; Paris; Pyrazoles; Retrospective Studies; Sample Size; Young Adult

2020
Deficit of circulating CD19
    British journal of haematology, 2020, Volume: 190, Issue:4

    Topics: Adolescent; ADP-ribosyl Cyclase 1; Adult; Aged; Anemia, Aplastic; Antigens, CD19; Antilymphocyte Serum; B-Lymphocyte Subsets; B-Lymphocytes, Regulatory; Benzoates; Bone Marrow; CD24 Antigen; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cyclosporine; Female; Humans; Hydrazines; Immunosuppressive Agents; Interleukin-10; Killer Cells, Natural; Lymphocyte Count; Lymphopenia; Male; Membrane Glycoproteins; Middle Aged; Pyrazoles; Receptors, Thrombopoietin; Young Adult

2020
Disappearance of monosomy 7 in a patient with aplastic anemia after eltrombopag treatment.
    Hematology (Amsterdam, Netherlands), 2020, Volume: 25, Issue:1

    Topics: Aged; Anemia, Aplastic; Benzoates; Chromosome Deletion; Chromosomes, Human, Pair 7; Female; Humans; Hydrazines; Pyrazoles

2020
[Eltrombopag combined with cyclosporine alone for treatment of very severe aplastic anemia: a case report].
    Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2019, 07-14, Volume: 40, Issue:7

    Topics: Anemia, Aplastic; Benzoates; Cyclosporine; Humans; Hydrazines; Immunosuppressive Agents; Pyrazoles

2019
Secondary myelodysplastic syndrome and leukemia in acquired aplastic anemia and paroxysmal nocturnal hemoglobinuria.
    Blood, 2020, 07-02, Volume: 136, Issue:1

    Topics: Age of Onset; Anemia, Aplastic; Antibodies, Monoclonal, Humanized; Benzoates; Bone Marrow; Chromosome Aberrations; Chromosomes, Human, Pair 7; Clonal Evolution; Clone Cells; Disease Progression; Granulocyte Colony-Stimulating Factor; Hemoglobinuria, Paroxysmal; Humans; Hydrazines; Leukemia, Myeloid, Acute; Models, Biological; Monosomy; Mutation; Myelodysplastic Syndromes; Oncogene Proteins, Fusion; Pyrazoles; Selection, Genetic; Telomere Shortening

2020
High-dose romiplostim accelerates hematologic recovery in patients with aplastic anemia refractory to eltrombopag.
    Leukemia, 2021, Volume: 35, Issue:3

    Topics: Adult; Aged; Anemia, Aplastic; Benzoates; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Hydrazines; Male; Middle Aged; Prognosis; Pyrazoles; Receptors, Fc; Recombinant Fusion Proteins; Recovery of Function; Retrospective Studies; Thrombopoietin; Young Adult

2021
An Eltrombopag Red (Plasma) Alert.
    Acta haematologica, 2021, Volume: 144, Issue:2

    Topics: Anemia, Aplastic; Benzoates; Bilirubin; Female; Humans; Hydrazines; Middle Aged; Plasma; Pyrazoles

2021
Romiplostim is effective for eltrombopag-refractory aplastic anemia: results of a retrospective study.
    International journal of hematology, 2020, Volume: 112, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Anemia, Aplastic; Anemia, Refractory; Benzoates; Drug Substitution; Drug Tolerance; Female; Follow-Up Studies; Humans; Hydrazines; Male; Middle Aged; Platelet Count; Prospective Studies; Pyrazoles; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Retrospective Studies; Thrombopoietin

2020
Eltrombopag is effective in patients with relapse/refractory aplastic anemia-report from a single center in China.
    Annals of hematology, 2020, Volume: 99, Issue:12

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anemia, Aplastic; Benzoates; China; Female; Follow-Up Studies; Hospitals, University; Humans; Hydrazines; Male; Middle Aged; Pyrazoles; Recurrence; Retrospective Studies; Treatment Outcome; Young Adult

2020
Aplastic anemia in a patient with CVID due to NFKB1 haploinsufficiency.
    Cold Spring Harbor molecular case studies, 2020, Volume: 6, Issue:6

    Topics: Anemia, Aplastic; Benzoates; Bone Marrow; Common Variable Immunodeficiency; Cyclosporine; Exome Sequencing; Female; Genetic Predisposition to Disease; Haploinsufficiency; Humans; Hydrazines; Middle Aged; NF-kappa B; NF-kappa B p50 Subunit; Pyrazoles; Signal Transduction

2020
Eltrombopag preferentially expands haematopoietic multipotent progenitors in human aplastic anaemia.
    British journal of haematology, 2021, Volume: 193, Issue:2

    Topics: Adolescent; Adult; Anemia, Aplastic; Antigens, CD34; Benzoates; Biopsy, Needle; Bone Marrow Cells; Brazil; Female; Flow Cytometry; Hematopoietic Stem Cells; Humans; Hydrazines; Immunosuppressive Agents; Male; Middle Aged; Multipotent Stem Cells; Pyrazoles; Receptors, Thrombopoietin

2021
Paediatric severe aplastic anaemia treatment: where to start?
    British journal of haematology, 2021, Volume: 192, Issue:3

    Topics: Anemia, Aplastic; Benzoates; Child; Humans; Hydrazines; Immunosuppression Therapy; Pyrazoles

2021
Effectiveness and safety of tacrolimus with or without eltrombopag, as a part of immunosuppressive treatment of aplastic anemia in adults: a retrospective case series.
    Annals of hematology, 2021, Volume: 100, Issue:4

    Topics: Adult; Aged; Anemia, Aplastic; Antilymphocyte Serum; Benzoates; Cyclosporine; Drug Eruptions; Female; Gingival Hypertrophy; Hirsutism; Humans; Hydrazines; Immunosuppressive Agents; Male; Middle Aged; Pyrazoles; Retrospective Studies; Tacrolimus

2021
Efficacy and safety of eltrombopag in the first-line therapy of severe aplastic anemia in children.
    Pediatric hematology and oncology, 2021, Volume: 38, Issue:7

    Topics: Anemia, Aplastic; Animals; Antilymphocyte Serum; Benzoates; Child; Cyclosporine; Female; Humans; Hydrazines; Immunosuppressive Agents; Male; Pyrazoles; Rabbits; Retrospective Studies; Treatment Outcome

2021
Eltrombopag in children with severe aplastic anemia.
    Pediatric blood & cancer, 2021, Volume: 68, Issue:8

    Topics: Anemia, Aplastic; Antilymphocyte Serum; Benzoates; Child; Cyclosporine; Humans; Hydrazines; Immunosuppressive Agents; Pyrazoles; Retrospective Studies; Treatment Outcome

2021
Predicting response of severe aplastic anemia to immunosuppression combined with eltrombopag.
    Haematologica, 2022, 01-01, Volume: 107, Issue:1

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anemia, Aplastic; Benzoates; Child; Child, Preschool; Humans; Hydrazines; Immunosuppression Therapy; Immunosuppressive Agents; Middle Aged; Pyrazoles; Retrospective Studies; Young Adult

2022
Role of eltrombopag in severe aplastic anemia treatment in children.
    Pediatrics and neonatology, 2021, Volume: 62, Issue:6

    Topics: Anemia, Aplastic; Benzoates; Child; Humans; Hydrazines; Pyrazoles

2021
Nationwide survey on the use of eltrombopag in patients with severe aplastic anemia: a report on behalf of the French Reference Center for Aplastic Anemia.
    Haematologica, 2018, Volume: 103, Issue:2

    Topics: Aged; Anemia, Aplastic; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Benzoates; Female; France; Humans; Hydrazines; Male; Middle Aged; Pyrazoles; Retrospective Studies; Salvage Therapy; Surveys and Questionnaires; Treatment Outcome

2018
Eltrombopag in the management of aplastic anaemia: real-world experience in a non-trial setting.
    Hematology (Amsterdam, Netherlands), 2018, Volume: 23, Issue:7

    Topics: Adult; Anemia, Aplastic; Benzoates; Biomarkers; Combined Modality Therapy; Disease Management; Drug Resistance; Female; Hematopoietic Stem Cell Transplantation; Humans; Hydrazines; Male; Pyrazoles; Recurrence; Thrombopoietin; Transplantation, Homologous; Treatment Outcome; Young Adult

2018
iPSC modeling of severe aplastic anemia reveals impaired differentiation and telomere shortening in blood progenitors.
    Cell death & disease, 2018, 01-26, Volume: 9, Issue:2

    Topics: Anemia, Aplastic; Benzoates; Case-Control Studies; Cell Differentiation; Cell Line; Cell Proliferation; Colony-Forming Units Assay; Fibroblasts; Hematopoietic Stem Cells; Humans; Hydrazines; Induced Pluripotent Stem Cells; Models, Biological; Pyrazoles; Telomerase; Telomere; Telomere Shortening

2018
Eltrombopag as initial monotherapy for severe aplastic anemia-a case report.
    Annals of hematology, 2018, Volume: 97, Issue:8

    Topics: Anemia, Aplastic; Benzoates; Female; Humans; Hydrazines; Middle Aged; Pyrazoles; Severity of Illness Index

2018
Eltrombopag mobilizes iron in patients with aplastic anemia.
    Blood, 2018, 05-24, Volume: 131, Issue:21

    Topics: Anemia, Aplastic; Benzoates; Biomarkers; Humans; Hydrazines; Iron; Pyrazoles; Treatment Outcome

2018
[Safety and efficacy of the use of eltrombopag in a case of severe acquired bone marrow aplasia].
    Anales de pediatria, 2019, Volume: 90, Issue:4

    Topics: Anemia, Aplastic; Benzoates; Child; Female; Humans; Hydrazines; Pyrazoles; Receptors, Thrombopoietin; Severity of Illness Index

2019
Upfront eltrombopag monotherapy induces stable hematologic remission in pediatric patients with nonsevere idiopathic aplastic anemia.
    Pediatric blood & cancer, 2018, Volume: 65, Issue:10

    Topics: Anemia, Aplastic; Benzoates; Child; Female; Humans; Hydrazines; Male; Pyrazoles; Remission Induction

2018
Are eltrombopag plasma and skin hyperpigmentation related? The eyes have it.
    American journal of hematology, 2019, Volume: 94, Issue:3

    Topics: Adult; Anemia, Aplastic; Benzoates; Color; Female; Gene Expression; Humans; Hydrazines; Hyperpigmentation; Pyrazoles; Receptors, Thrombopoietin; Severity of Illness Index

2019
Eltrombopag for Delayed Platelet Recovery and Secondary Thrombocytopenia Following Allogeneic Stem Cell Transplantation in Children.
    Journal of pediatric hematology/oncology, 2019, Volume: 41, Issue:1

    Topics: Adolescent; Allografts; Anemia, Aplastic; Benzoates; Child; Gaucher Disease; Hematopoietic Stem Cell Transplantation; Humans; Hydrazines; Male; Platelet Count; Pyrazoles; Receptors, Fc; Recombinant Fusion Proteins; Recovery of Function; Thrombocytopenia; Thrombopoietin

2019
Aptamer-based proteomics of serum and plasma in acquired aplastic anemia.
    Experimental hematology, 2018, Volume: 68

    Topics: Adolescent; Adult; Aged; Anemia, Aplastic; Aptamers, Nucleotide; Benzoates; Biomarkers; Blood Proteins; Child; Child, Preschool; Female; Humans; Hydrazines; Immunosuppressive Agents; Male; Middle Aged; Molecular Targeted Therapy; Proteomics; Pyrazoles; Receptors, Thrombopoietin; Young Adult

2018
Clinical and morphological predictors of outcome in older aplastic anemia patients treated with eltrombopag.
    Haematologica, 2019, Volume: 104, Issue:11

    Topics: Aged; Aged, 80 and over; Anemia, Aplastic; Benzoates; Biomarkers; Biopsy; Bone Marrow; Humans; Hydrazines; Molecular Targeted Therapy; Prognosis; Pyrazoles; Treatment Outcome

2019
Eltrombopag combined with cyclosporine may have an effect on very severe aplastic anemia.
    Annals of hematology, 2019, Volume: 98, Issue:8

    Topics: Anemia, Aplastic; Benzoates; Cyclosporine; Drug Therapy, Combination; Female; Hematopoiesis; Humans; Hydrazines; Immunosuppressive Agents; Middle Aged; Pyrazoles; Uterine Hemorrhage

2019
Use of eltrombopag in aplastic anemia in Europe.
    Annals of hematology, 2019, Volume: 98, Issue:6

    Topics: Adult; Aged; Anemia, Aplastic; Benzoates; Drug Evaluation; Drug Utilization; Europe; Female; Follow-Up Studies; Humans; Hydrazines; Kaplan-Meier Estimate; Male; Middle Aged; Myelodysplastic Syndromes; Proportional Hazards Models; Pyrazoles; Receptors, Thrombopoietin; Retrospective Studies; Young Adult

2019
The oral microbiome of patients undergoing treatment for severe aplastic anemia: a pilot study.
    Annals of hematology, 2019, Volume: 98, Issue:6

    Topics: Adult; Aged; Anemia, Aplastic; Anti-Bacterial Agents; Antilymphocyte Serum; Benzoates; Biodiversity; Cyclosporine; Dental Health Surveys; DNA, Bacterial; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Hydrazines; Immunocompromised Host; Immunosuppressive Agents; Male; Microbiota; Middle Aged; Mouth; Pilot Projects; Pyrazoles; Ribotyping; Sequence Analysis, DNA; Smoking; T-Lymphocytes; Tongue; Young Adult

2019
A rare side effect: eltrombopag associated hyperpigmentation.
    Giornale italiano di dermatologia e venereologia : organo ufficiale, Societa italiana di dermatologia e sifilografia, 2020, Volume: 155, Issue:6

    Topics: Aged; Anemia, Aplastic; Benzoates; Cyclosporine; Drug Therapy, Combination; Female; Humans; Hydrazines; Melanosis; Pyrazoles

2020
Management of acquired aplastic anemia in children : A single center experience.
    Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis, 2019, Volume: 58, Issue:4

    Topics: Adolescent; Allografts; Anemia, Aplastic; Benzoates; Child; Child, Preschool; Cyclophosphamide; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Hydrazines; Immunosuppression Therapy; Levamisole; Male; Pyrazoles; Retrospective Studies

2019
Iron mobilization in a real life cohort of aplastic anemia patients treated with eltrombopag.
    American journal of hematology, 2019, Volume: 94, Issue:9

    Topics: Anemia, Aplastic; Benzoates; Female; Follow-Up Studies; Humans; Hydrazines; Iron; Male; Prospective Studies; Pyrazoles

2019
Eltrombopag: wielding a double-edged sword?
    Blood, 2019, 06-13, Volume: 133, Issue:24

    Topics: Anemia, Aplastic; Benzoates; Genomics; Humans; Hydrazines; Pyrazoles

2019
Eltrombopag: a stem cell cookie?
    Blood, 2014, Mar-20, Volume: 123, Issue:12

    Topics: Anemia, Aplastic; Benzoates; Female; Hematopoiesis; Humans; Hydrazines; Male; Pyrazoles

2014
Successful treatment of aplastic anaemia associated with HIV infection with eltrombopag: implications for a possible immunomodulatory role.
    AIDS (London, England), 2014, Nov-28, Volume: 28, Issue:18

    Topics: Aged; Anemia, Aplastic; Benzoates; HIV Infections; Humans; Hydrazines; Immunologic Factors; Male; Pyrazoles; T-Lymphocyte Subsets; T-Lymphocytes, Regulatory; Th1 Cells; Th17 Cells

2014
Eltrombopag interference in routine chemistry testing.
    Annals of clinical biochemistry, 2016, Volume: 53, Issue:Pt 5

    Topics: Anemia, Aplastic; Artifacts; Benzoates; Blood Chemical Analysis; Cholesterol; Female; Humans; Hydrazines; Middle Aged; Phosphates; Pyrazoles; Thrombocytopenia; Triglycerides

2016
Supportive Care and Newer Therapies in Aplastic Anaemia.
    The Journal of the Association of Physicians of India, 2015, Volume: 63, Issue:3 Suppl

    Topics: Anemia, Aplastic; Benzoates; Blood Transfusion; Hematologic Agents; Hematopoietic Stem Cell Transplantation; Hemorrhage; Humans; Hydrazines; Immunosuppression Therapy; Opportunistic Infections; Prognosis; Pyrazoles; Secondary Prevention

2015
Guidelines for the diagnosis and management of adult aplastic anaemia.
    British journal of haematology, 2016, Volume: 172, Issue:2

    Topics: Aged; Anemia, Aplastic; Benzoates; Blood Component Transfusion; Female; Hematopoietic Stem Cell Transplantation; Hemoglobinuria, Paroxysmal; Humans; Hydrazines; Immunosuppressive Agents; Opportunistic Infections; Pregnancy; Pregnancy Complications, Hematologic; Pyrazoles; Severity of Illness Index

2016
The thrombopoietin mimetics eltrombopag and romiplostim in the treatment of refractory aplastic anaemia.
    British journal of haematology, 2017, Volume: 176, Issue:6

    Topics: Adult; Aged; Anemia, Aplastic; Benzoates; Female; Humans; Hydrazines; Male; Middle Aged; Pyrazoles; Receptors, Fc; Recombinant Fusion Proteins; Thrombopoietin; Young Adult

2017
Morbilliform eruption related to eltrombopag: emerging data on the cutaneous toxicity of thrombopoietin receptor agonists.
    Dermatology online journal, 2016, Jun-15, Volume: 22, Issue:6

    Topics: Adult; Anemia, Aplastic; Back; Benzoates; Drug Eruptions; Humans; Hydrazines; Male; Pyrazoles; Receptors, Thrombopoietin; Thrombocytopenia

2016
A promising new treatment for refractory aplastic anemia.
    The New England journal of medicine, 2012, Jul-05, Volume: 367, Issue:1

    Topics: Anemia, Aplastic; Benzoates; Female; Humans; Hydrazines; Male; Pyrazoles

2012
Eltrombopag in refractory aplastic anemia.
    The New England journal of medicine, 2012, 09-20, Volume: 367, Issue:12

    Topics: Anemia, Aplastic; Benzoates; Female; Humans; Hydrazines; Male; Pyrazoles

2012
Eltrombopag in refractory aplastic anemia.
    The New England journal of medicine, 2012, 09-20, Volume: 367, Issue:12

    Topics: Anemia, Aplastic; Benzoates; Female; Humans; Hydrazines; Male; Pyrazoles

2012
[The results of attack polychemotherapy in broncho-pleuro-pulmonary cancer. Phytohemagglutinin in the prevention and treatment of hematologic complications of antimitotics].
    Le Poumon et le coeur, 1968, Volume: 24, Issue:1

    Topics: Anemia, Aplastic; Antibiotics, Antineoplastic; Antineoplastic Agents; Azirines; Bronchial Neoplasms; Drug Synergism; Fluorouracil; Humans; Hydrazines; Injections, Intramuscular; Injections, Intravenous; Lectins; Lung Neoplasms; Mechlorethamine; Mercaptopurine; Methotrexate; Pleural Neoplasms; Vinblastine

1968